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Summary
 
We analyzed the immune responses evoked by a series of overlapping peptides to better under-
stand the molecular basis for respiratory syncytial virus (RSV) G protein–induced eosinophilia
in BALB/c mice. In vitro stimulation of spleen cells from natural G protein–primed mice
 
showed dominant proliferative and cytokine (interferon [IFN]-
 
g
 
 and interleukin [IL]-5) re-
sponses to a peptide encompassing amino acids 184–198. Mice vaccinated with peptide 184–
198 conjugated to keyhole limpet hemocyanin showed significant pulmonary eosinophilia
(39.5%) after challenge with live RSV. In contrast, mice immunized with a peptide (208–222)
conjugate associated with induction of IFN-
 
g
 
 secreting spleen cells did not exhibit pulmonary
 
eosinophilia after challenge. The in vivo depletion of CD4
 
1
 
 cells abrogated pulmonary eosino-
philia in mice vaccinated with the peptide 184–198 conjugate, whereas the depletion of CD8
 
1
 
cells had a negligible effect. Therefore, we have identified an association between peptide 184–
198 of natural G protein and the CD4
 
1
 
 T cell–mediated induction of pulmonary eosinophilia
after live RSV challenge. Out of 43 human donors, 6 provided peripheral blood mononuclear
cells that showed reactivity to G protein from RSV A2, 3 of which responded to peptide 184–
198. The results have important implications for the development of a vaccine against RSV. 
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he continued interest in the attachment (G) glycopro-
tein as a component of any subunit vaccine strategy is
predicated by its ability to induce and augment protective
immune responses to respiratory syncytial virus (RSV) in-
fection (1–3). However, a correlation between immuniza-
tion with purified natural G protein or recombinant vac-
cinia constructs and priming for atypical pulmonary
eosinophilia was observed in the BALB/c mouse model of
RSV disease (1, 4). This phenomenon was reminiscent of
the enhanced disease observed in human recipients of for-
malin-inactivated RSV (FI-RSV) upon subsequent infec-
tion with live RSV (5). Both FI-RSV and natural G pro-
tein have been shown to induce Th2 immune responses,
whereas live attenuated viral vaccines are associated with
Th1 responses (1, 6–10). Accordingly, the depletion of IL-5,
a cytokine associated with Th2 immune responses, signifi-
cantly reduced eosinophilia in bronchoalveolar lavages
(BAL) of mice that had been vaccinated with G protein be-
fore challenge with live RSV (1). The response was shown
to be T cell mediated by transfer of G protein–specific
CD4
 
1
 
 T cell lines into naive recipient mice, resulting in
atypical pulmonary inflammatory responses after challenge
(4, 10). The gene encoding RSV G protein contains alter-
 
native initiation codons resulting in both full-length and
truncated forms of the protein, the latter of which is se-
creted (11). Recent evidence suggests that the secreted
form of G protein is involved in immunopathology and
pulmonary eosinophilia (12). Therefore, the goal of this
study was to dissect the molecular mechanisms underlying
the immunopathology of natural G protein.
 
Materials and Methods
 
Mice.
 
Female BALB/c mice (aged 7–9 wk) were purchased
from Taconic Farms, Inc. (Germantown, NY). All mice were
housed in a facility approved by the American Association for
Accreditation of Laboratory Animal Care.
 
Preparation and Use of Protein Antigens.
 
RSV G protein was im-
munoaffinity purified (1) from the A2 strain of RSV grown in
Vero cells (ATCC CCL 81 [American Type Culture Collection,
Rockville, MD]). Intramuscular immunizations were performed
at 0 and 4 wk with 0.1 ml of PBS containing 1 
 
m
 
g of purified G
protein and 20 
 
m
 
g QS-21 (Aquila Biopharmaceuticals, Inc.,
Worcester, MA) as adjuvant. For RSV vaccinations and chal-
lenges, 1–2 
 
3
 
 10
 
6
 
 PFU of infectious RSV A2 was clarified from
HEp-2 cells (ATCC CCL 23) by low speed centrifugation and
administered intranasally in a 50 
 
m
 
l vol.
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Preparation and Use of Peptide Antigens.
 
A series of overlapping
peptides was synthesized by Genosys Biotechnologies, Inc. (The
Woodlands, TX). The peptides were synthesized as 15-mers to
overlap by seven amino acids. The resultant series encompassed
the secreted form (amino acids 48–294) of G protein (9, 11). In
addition, peptide 17 was synthesized as a 17-mer to span amino
acids 171–187. The purity of the peptides was determined by
mass spectometry to be 
 
.
 
90%.
Peptides 19 and 22 were conjugated to maleimide-activated
(13) keyhole limpet hemocyanin (KLH) using an Imject
 
Ò
 
 acti-
vated conjugation kit (Pierce Chemical Co., Rockford, IL). Since
the mechanism of conjugation was dependent upon a chemical
reaction between maleimide groups in KLH and sulfhydryl
groups in the peptide, a cysteine was added to the 3
 
9
 
 end of peptide
22 (208–222). The degree to which the peptides were conjugated
was determined by loss of thiol groups in the peptide using Ell-
man’s reagent (Pierce Chemical Co.). The extent of conjugation
(typically 50–80 
 
m
 
g peptide per mg of KLH) compared favorably
with that previously seen for the attachment of peptides to KLH
(14). For study of the induction of eosinophilia, 250 
 
m
 
g of each
peptide–KLH conjugate was adjuvanted with 20 
 
m
 
g QS-21 in 0.1
ml of PBS and injected intramuscularly at 0 and 4 wk. The mice
were challenged 2 wk after secondary vaccination. BAL cells were
isolated 7 d later and stained as described previously (1). The pro-
portion of eosinophils was enumerated by analyzing a minimum
of 400 leukocytes per slide. The results are expressed as mean per-
centage of eosinophils (
 
6
 
 1 SD).
 
In Vivo Depletion of T Cell Subsets.
 
mAbs to murine CD4,
GK1.5 (ATCC TIB 207), and murine CD8, 53-6.72 (ATCC TIB
105), were purified from hybridoma culture supernatants over a
recombinant protein G column (Amersham Pharmacia Biotech,
Piscataway, NJ). As control, purified rat IgG was purchased from
Calbiochem (San Diego, CA). mAbs were administered at 14 and
20 d after final immunization in doses of 750 and 250 
 
m
 
g per
mouse, respectively. The effectiveness of the depletion regime was
monitored on a FACScan
 
Ò
 
 (Becton Dickinson, Mountain View,
CA) using PE-conjugated anti–mouse CD4 (L3T4) and FITC-con-
jugated anti–mouse CD8 (Ly-2) (PharMingen, San Diego, CA).
 
In Vitro Expansion of Immunocytes and Cytokine Analyses.
 
Spleens
were isolated from groups of five mice 2 wk after secondary vaccina-
tion with G/QS-21 and were converted to single cell suspensions as
previously described (1). As controls, purified G protein, diphtheria
toxin cross-reactive protein (CRM197), and Con A were added at
final concentrations of 2.5 and 0.5 
 
m
 
g/ml, 10 
 
m
 
g/ml, and 1 
 
m
 
g/ml,
respectively. After 3 d in culture, supernatants were pooled from
triplicate wells and assayed for IFN-
 
g
 
 and IL-5 by antigen-capture
ELISA (1, 15). Data are presented in picograms per milliliter for IL-5
and units per milliliter for IFN-
 
g
 
, where 1 U of IFN-
 
g
 
 bioactivity is
defined as the reciprocal of the endpoint dilution that protects 50% of
mouse L cells from viral destruction (16). The remaining cultures
were pulsed with 1 
 
m
 
Ci of [
 
3
 
H]thymidine and subsequently har-
vested to quantify [
 
3
 
H]thymidine incorporation into DNA.
Heparinized human peripheral blood was collected from nor-
mal adult donors and separated using Ficoll-Hypaque (Amersham
Pharmacia Biotech) centrifugation. Cells were cultured with pep-
tides in RPMI 1640 medium containing 10% AB
 
2
 
 serum (Bio-
cell, Rancho Dominguez, CA) at a concentration of 50 
 
m
 
g/ml.
As controls, cells were cultured with CRM 197 (30 
 
m
 
g/ml),
PHA (5 
 
m
 
g/ml), or medium alone.
 
Statistical Analyses.
 
Significant differences between groups
were determined by the Tukey-Kramer honestly significant dif-
ference multiple comparisons test using JMP
 
Ò
 
 statistical discovery
software (SAS Institute Inc., Cary, NC).
 
Results
 
Lymphoproliferative and Cytokine Responses of Natural G
Protein Primed Spleen Cells Stimulated with Synthetic Pep-
tides.
 
To localize T cell epitopes, spleen cells from G pro-
tein–vaccinated mice were stimulated with a series of 15-
mers encompassing the secreted form of RSV G protein
(11). The data (Fig. 1) demonstrated that maximal prolif-
eration was obtained after stimulation with peptide 19
(amino acids 184–198). Proliferation was 16-fold above
background levels and far exceeded that attained by other
G protein–derived peptides. In addition, the magnitude of
the response to peptide 19 (3.6 
 
3
 
 10
 
4
 
 cpm) was compara-
ble to that attained by purified natural G protein, which
yielded mean proliferation levels of 3 and 4.7 
 
3
 
 10
 
4
 
 cpm
for concentrations of 0.5 and 2.5 
 
m
 
g/ml, respectively. The
proliferative data for peptides 3–17 and 26–31 were at or
near background levels. The highest levels of IFN-
 
g
 
 and
IL-5 were also observed after stimulation with peptide 19
(Fig. 2). Moreover, the levels were equivalent to or greater
than those obtained after restimulation with natural G pro-
tein. Several other peptides (20, 22, 24, and 25) appeared
to induce lower but noteworthy levels of IFN-
 
g
 
 secretion
in the absence of demonstrable IL-5 production (Fig. 2).
IL-5 was also observed at lower levels after stimulation
with peptides 2 and 24. Both IFN-
 
g
 
 and IL-5 were ob-
served in cultures that were stimulated with purified natural
G protein and Con A. Collectively, the data suggest that a
region spanning amino acids 184–198 contains the domi-
nant epitope(s) in natural G protein recognized by T cells
in BALB/c mice.
 
Peptide 19 Conjugated to KLH Primes for Pulmonary Eosino-
philia.
 
To affirm a direct role in priming for pulmonary
eosinophilia, peptide 19 was compared with peptide 22,
which stimulated IFN-
 
g
 
 production in the absence of IL-5
(Fig. 2). To ensure sufficient immunogenicity, the peptides
were conjugated to maleimide-activated KLH. Statistically
significant pulmonary eosinophilia was observed in mice
primed with either peptide 19–KLH (39.5 
 
6
 
 8.0%) or G
protein (63 
 
6
 
 1.9%) when compared with mice vaccinated
with adjuvant alone (2.5 
 
6
 
 2.0%) (Fig. 3). In contrast, the
level of eosinophilia associated with peptide 22–KLH (4.9 
 
6
Figure 1. Proliferative re-
sponses of BALB/c splenocytes
to peptides of RSV G protein.
BALB/c mice were vaccinated at
0 and 4 wk with 1 mg G protein
adjuvanted with QS-21 (20 mg
per dose). 2 wk after secondary
vaccination, splenocytes were
isolated, pooled, and cultured for
4 d with synthetic peptides (50
mg/ml), natural G protein (0.5
[G(0.5)] or 2.5 [G(2.5)] mg/ml),
Con A, CRM197 (CRM), or
medium alone (Med). Con A
stimulation of splenocytes resulted in mean cpm of 94,746 6 8,005. Data
are presented as the mean cpm (6 1 SD) of triplicate wells. The experi-
ment is representative of five independent experiments with qualitatively
similar results. 
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3.3%) remained at background levels. It was noteworthy
that peptide 22 was immunogenic. 2 wk after final vaccina-
tion, the geometric mean endpoint anti-RSV G protein
IgG antibody titers of mice vaccinated with peptide 19–
KLH or peptide 22–KLH were 1517 and 5611, respec-
tively. Thus, although humoral immune responses were
generated to each of the peptide conjugates, the induction
of aberrant eosinophilia was limited to those mice that re-
ceived natural G protein or peptide 19–KLH.
 
In Vivo Depletion of T Cell Subsets and the Induction of Eo-
sinophilia.
 
To determine whether peptide 19–KLH–asso-
ciated eosinophilia was mediated by CD4
 
1
 
 cells, a series of
depletion experiments were performed using mAbs to
CD4 or CD8 surface molecules. The depletion of CD4
 
1
 
cells resulted in a significant reduction in pulmonary eosin-
ophilia in mice vaccinated with either G/QS-21 or peptide
19–KLH/QS-21 (Table 1). Specifically, treatment with
anti-CD4 mAb significantly reduced pulmonary eosino-
philia from 67.2 
 
6
 
 8.5% and 29.6 
 
6
 
 13.3% to 8.1 
 
6
 
 4.7%
and 0.75 
 
6
 
 0.6%, respectively. The corresponding effect of
anti-CD8 mAb treatment had minimal impact. After chal-
lenge, eosinophilia persisted at 63.8 
 
6
 
 6.4 and 32.8 
 
6
 
10.3% for G- and peptide 19–KLH–vaccinated mice, re-
spectively. The data demonstrate that CD4
 
1
 
 cells are re-
quired for the pulmonary eosinophilic response in natural
G protein– or peptide 19–KLH–immunized mice.
 
Human Peripheral Blood Cell Responses after Stimulation
with Synthetic Peptides.
 
The PBMCs from a panel of do-
nors were tested for reactivity to purified natural G protein
from the A2 strain of RSV. Subsequently, the cells from six
reactive donors were cultured in the presence of the syn-
thetic peptides (Fig. 4). A strong proliferative response to
peptide 19 was observed for donor 100 (mean stimulation
index, 8.5). A variety of specific proliferative responses
were apparent to peptide 19 in donors 9 and 20 with mean
stimulation indices of threefold in each case. In addition to
peptide 19, a variety of specific proliferative responses were
also seen to other G protein–derived peptides. For example,
PBMCs isolated from donor 100 also responded to peptides 2
and 15 with mean stimulation indices of 13.5 and 10.0, re-
spectively. Responses to peptides 4, 9, and 29 were also
Figure 2. The secretion of IFN-g and IL-5 after stimulation with peptides
of RSV G protein. Pooled supernatants from triplicate wells (Fig. 1) were
collected after 3 d of stimulation. For IFN-g (A), the lower limit of detection
was 0.84 U/ml. For IL-5 (B), the lower limit of detection was 173 pg/ml.
Figure 3. Peptide 19 conju-
gated to KLH primes for pulmo-
nary eosinophilia. BALB/c mice
(five mice per group) were vac-
cinated intramuscularly at 0 and
4 wk. The vaccines consisted of
250 mg of KLH (KLH); 250 mg
KLH containing either 13 mg pep-
tide 19 (19-KLH) or 11 mg pep-
tide 22 (22-KLH); 250 mg of un-
conjugated peptides 19 or 22 (19
and 22, respectively), 1 mg natu-
ral G protein, or PBS alone.
Each vaccine was adjuvanted
with QS-21 (20 mg/dose). 2 wk after secondary vaccination, mice were
challenged with RSV. Data are presented as the mean percent (6 1 SD)
eosinophils in BAL fluids 7 d after challenge. Asterisk denotes significant
differences for G protein or 19–KLH–vaccinated mice compared to con-
trol mice injected with either PBS or KLH. The data are representative of
three experiments.
 
Table 1.
 
CD4 T Cells Mediate the Eosinophilic Response Induced by RSV G Protein and Peptide 19–KLH
 
Vaccine Antigen Antibody treatment Percentage of CD4
 
1
 
 cells Percentage of CD8
 
1
 
 cells Percentage of BAL eosinophils
G protein rat Ig 21.2 8.5 67.2 
 
6
 
 8.5
G protein anti-CD4 1.5 15.0 8.1 
 
6
 
 4.7
 
**
 
G protein anti-CD8 24.4 2.7 63.8 
 
6
 
 6.4
Peptide 19–KLH rat Ig 19.0 7.7 29.6 
 
6
 
 13.3
Peptide 19–KLH anti-CD4 0.3 20.0 0.75 
 
6
 
 0.6
 
**
 
Peptide 19–KLH anti-CD8 27.4 2.8 32.8 
 
6
 
 10.3
RSV none 25.8 11.2 0.7 
 
6 1.0
BALB/c mice (five mice per group) were vaccinated intramuscularly at 0 and 4 wk with natural G protein (1 mg) or 250 mg KLH containing 18 mg
peptide 19, or intranasally with RSV (106 PFU). The indicated antibodies were administered intraperitoneally at 14 and 20 d after immunization.
The mice were challenged with RSV the next day and pulmonary eosinophilia was assessed 7 d later. Data are presented as mean percentage eosino-
phils in BAL (6 1 SD), and percentage of CD41 and CD81 cells relative to total splenic lymphocytes. Significant differences (**) are indicated com-
pared to control mice given rat IgG. A second experiment yielded similar results.1970 RSV G Protein Eosinophilia
noteworthy for donor 100, achieving a mean stimulation
index of at least fivefold in each case (data not shown).
Discussion
This study provides the first evidence that a specific
amino acid sequence (184–198) is sufficient to mimic puri-
fied natural G protein and predispose BALB/c mice for
atypical pulmonary eosinophilia after challenge. Collec-
tively, the data show that this peptide (AICKRIPNKK-
PGKKT) primes for pulmonary eosinophilia by stimulating
the expansion of CD41 T cells destined to secrete IL-5, a
cytokine associated with the induction and recruitment of
eosinophils (17). We propose a model of immune priming
in which one or more Th cell epitopes within peptide 19
control the qualitative nature of subsequent immune re-
sponses, resulting in a profound skewing toward the Th2
phenotype. That the peptide component of the TCR–
MHC interaction can modulate the quality of the immune
response between Th1 and Th2 phenotypes has previously
been shown by altering peptide sequences (18, 19). How-
ever, it remains possible that the 15 amino acids that com-
prise peptide 19 contain more than one T cell epitope,
each with a discrete ability to stimulate a Th1 versus Th2
response. In favor of this hypothesis, an analysis of the se-
quence of peptide 19 indicates that it contains three poten-
tial T cell epitopes restricted to MHC class II I-Ed that align
closely at the critical 1, 4, 6, and 9 anchor residues (I, K or
R, I, and K, respectively) (20). Each of these putative se-
quences are consistent with class II binding based upon the
publication of known ligands generated by the biochemical
isolation of MHC-associated peptides or by peptide bind-
ing assays (20). The mutation of peptide 19 (AICKRIP-
NKKPGKKT) to one that disrupts the critical MHC-bind-
ing anchor regions of two of the potential T cell epitopes
(AICGRGPNGKPGKKT) completely abrogated the abil-
ity of this peptide to predispose mice for pulmonary eosino-
philia (data not shown).
We originally identified peptide 19 as the specific amino
acid sequence that stimulated a dominant proliferative re-
sponse to natural G protein (21). The data presented here
provide a positive correlation between the peptide encom-
passing amino acids 184–198 of G protein and the predis-
position for pulmonary eosinophilia. As an extension to
our studies, recent experiments showed that the predisposi-
tion for pulmonary eosinophilia in BALB/c mice was lost
in a vaccinia virus construct containing a frameshift muta-
tion in the G protein gene at amino acids 193–273 (22).
The results further demonstrated that the mutated G pro-
tein gene was able to protect mice against subsequent virus
challenge (22), possibly due to the presence of previously
identified protective B cell epitopes that persist in the trun-
cated construct (23). In this regard, it is interesting to spec-
ulate that once the dominant T cell epitope(s) contained
within peptide 19 is deleted, subdominant T cell epitopes
will provide the requisite T cell help necessary for protec-
tive immunity in the absence of priming for pulmonary pa-
thology. The murine data presented here identify a number
of peptide candidates that stimulate IFN-g secretion (e.g.,
peptides 20, 22, 24, and 25) and may function in this ca-
pacity. Similarly, our human data suggested a number of
peptides (e.g., for donor 100; peptides 2, 4, 9, 15, and 29)
that stimulated proliferation of PBMCs. Thus, for seroneg-
ative populations, the results argue that a vaccine for RSV
should be genetically modified at amino acids 184–198 of
G protein. This vaccine would not bias recipients for atyp-
ical pulmonary disease, but would retain an ability to pro-
tect against subsequent RSV challenge.
Although it is possible for the TCR ligand to effect a
Th1 versus Th2 transition, other mechanisms of immune
control may be at play. The appearance of both IFN-g and
IL-5 in the supernatants of G protein–primed splenocytes
restimulated with peptide 19 may result from the genera-
tion of both Th1 and Th2 clones, or Th0 cells (24, 25).
The phenomenon may also be explained by the relative ab-
sence of CD81 T cells. CD81 T cells are an important
source of IFN-g and may modulate CD41 T cell immune
responses (26, 27). Indeed, we have previously shown only
a low level of splenic cytotoxic T cell activity in response
to G/QS-21 vaccination (1). Thus, the most favorable
RSV vaccine strategy for seronegative populations would
consist of components that, while not priming for immu-
nopathological sequelae, achieve a balanced immune re-
sponse mediated by protective CD41 and CD81 cells.
In this study, we have shown that vaccination with a
specific peptide of RSV G protein is sufficient to bias atyp-
ical pulmonary eosinophilia after challenge, although con-
tributions from other amino acid sequences within the
secretory form of RSV G protein cannot be ruled out. For
example, peptides 2 and 24 stimulated the production of
low levels of IL-5 from G protein–primed splenocytes.
However, recent studies suggest that peptide 2 is not suffi-
cient to predispose mice for pulmonary eosinophilia (22).
The data do imply that peptide 19 contains the antigenic
determinants responsible for atypical pulmonary eosino-
philia in mice. The proliferative response of human PBMCs
suggests that peptide 19 is important in human immune re-
sponses to RSV (28).
Figure 4. Proliferative re-
sponses of human PBMCs to
peptides of RSV G protein. PB-
MCs from 6 out of 43 donors
with reactivity to G protein from
the A2 strain of RSV were cul-
tured in the presence of peptide
19 (50 mg/ml), natural G protein
(3 mg/ml), PHA (5 mg/ml), or
medium alone. PHA stimulation
of PBMCs ranged from 22,945
to 55,619 cpm. Data are pre-
sented as the mean SI obtained
from triplicate cultures.1971 Tebbey et al. Brief Definitive Report
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